Attention deficit hyperactivity disorder

Treatment Phase: Initial treatment

Treatment criteria:

• Must be treated by a paediatrician or psychiatrist.

Clinical criteria:

• The condition must be or have been diagnosed according to the DSM-5 criteria,

AND

• Patient must have a contraindication to dexamfetamine, methylphenidate or lisdexamfetamine as specified in TGA-approved product information; OR

• Patient must have a comorbid mood disorder that has developed or worsened as a result of dexamfetamine, methylphenidate or lisdexamfetamine treatment and is of a severity necessitating treatment withdrawal; OR

• Patient must be at an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal if given a stimulant treatment with another agent; OR

• Patient must have experienced adverse reactions of a severity necessitating permanent treatment withdrawal following treatment with dexamfetamine, methylphenidate and lisdexamfetamine (not simultaneously).

Population criteria:

• Patient must be or have been diagnosed between the ages of 6 and 17 years inclusive.

Attention deficit hyperactivity disorder

Treatment Phase: Continuing treatment

Clinical criteria:

• Patient must have previously received PBS-subsidised treatment with this drug for this condition,

AND

• Patient must have a contraindication to dexamfetamine, methylphenidate or lisdexamfetamine as specified in TGA-approved product information; OR

• Patient must have a comorbid mood disorder that has developed or worsened as a result of dexamfetamine, methylphenidate or lisdexamfetamine treatment and is of a severity necessitating treatment withdrawal; OR

• Patient must be at an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal if given a stimulant treatment with another agent; OR

• Patient must have experienced adverse reactions of a severity necessitating permanent treatment withdrawal following treatment with dexamfetamine, methylphenidate and lisdexamfetamine (not simultaneously).

Attention deficit hyperactivity disorder

Treatment Phase: Initial treatment

Treatment criteria:

• Must be treated by a paediatrician or psychiatrist.

Clinical criteria:

• The condition must be or have been diagnosed according to the DSM-5 criteria,

AND

• Patient must be receiving a maximum tolerated dose (MTD) of stimulant (dexamfetamine, methylphenidate or lisdexamfetamine) which has been stable for at least four weeks,

AND

• The treatment must be adjunctive to ongoing maximum tolerated dose (MTD) of stimulant (dexamfetamine, methylphenidate or lisdexamfetamine),

AND

• Patient must be experiencing residual moderate to severe ADHD symptoms resulting in impaired functioning (social, academic or occupational), present in at least one setting (home, nursery/school/college/work, friends or family homes or other environment).

Population criteria:

• Patient must be or have been diagnosed between the ages of 6 and 17 years inclusive.

Attention deficit hyperactivity disorder

Treatment Phase: Continuing treatment

Clinical criteria:

• Patient must have previously received PBS-subsidised treatment with this drug for this condition,

AND

• The treatment must be adjunctive to ongoing maximum tolerated dose (MTD) of stimulant (dexamfetamine, methylphenidate or lisdexamfetamine).